Cytoreductive surgery and adjuvant immunotherapy: a new management paradigm for metastatic melanoma.
Although patients with metastatic disease are usually not offered surgery as part of their comprehensive treatment plan, the authors suggest that surgical reduction of the tumor burden may enhance the host immune response and create a favorable setting for the use of active specific immunotherapy.